Resverlogix Corp (RVXCF) 0.5695 $RVXCF
Resverlogix Corporate Update Conference Call & Webcast Announcement
PR Newswire - Wed Oct 01, 1:00PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.64 (-0.03)
Resverlogix Corp. Closes Additional $30 million from Citibank Loan
PR Newswire - Fri Aug 15, 4:00PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.64 (-0.03)
Resverlogix Corp. Shareholders Approve Additional $30 million from Citibank Loan
PR Newswire - Wed Aug 13, 4:01PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.64 (-0.03)
Restenosis - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fzlqdr/restenosis) has announced the addition of the "Restenosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Restenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restenosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Restenosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Restenosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shire Plc - Resverlogix Corp. - CytoTools AG - Angelini Group - Viron Therapeutics, Inc. - AIM Therapeutics Inc. - CSPC NBP Pharmaceutical Co.,ltd - XBiotech USA, Inc. For more information visit http://www.researchandmarkets.com/research/fzlqdr/restenosis
SHPG: 197.80 (+1.93)
CounterPath to Present at Needham Growth Conference
Marketwire Canada - Thu Jan 09, 6:57PM CST
CounterPath Corporation (NASDAQ:CPAH)(TSX:CCV), an award-winning provider of desktop and mobile VoIP software products and solutions, announces that Donovan Jones, President and Chief Executive Officer, will present at the 16th Annual Needham Growth Conference. Mr. Jones will outline CounterPath's VoIP software and services, its customer relationships, its IP portfolio and the sector outlook.
CCV.TO: 1.15 (+0.20), CPAH: 1.04 (+0.15), ISIS: 46.43 (+0.57), MRK: 55.85 (-0.60), BMY: 54.20 (+0.67), MNTA: 11.08 (+0.11), NVS: 92.35 (+2.14)
Global Encephalomyelitis Pipeline Review Report - H2 2013
M2 - Fri Dec 20, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/svxp6q/encephalomyelitis) has announced the addition of the "Encephalomyelitis - Pipeline Review, H2 2013" report to their offering. 'Encephalomyelitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Encephalomyelitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Encephalomyelitis. Scope - A snapshot of the global therapeutic scenario for Encephalomyelitis. - A review of the Encephalomyelitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Encephalomyelitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Encephalomyelitis Therapeutics Development - Takeda Pharmaceutical Company Limited - Elan Corporation, plc - Hadasit Medical Research Services & Development Ltd - Compugen Ltd. - Array BioPharma Inc. - Resverlogix Corp. - KAHR medical Ltd. - Cognosci, Inc. - Encephalomyelitis - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Route of Administration - Assessment by Molecule Type Drug Profiles - IRX-5183 - KAHR-101 - KAHR-104 - COG-112 - Antiarrhythmic Drug - Phosphodiesterase Type 5 Inhibitors - Cholesterol Absorption Inhibitor - CGEN-15021 - CGEN-15091 - RVX-297 - AR-460770 - VCE-003 - VCE-004 - PP-090-45 - COG-133 - Thymulin - thymopentin - TAK-779 - Soluble Immune Response Suppressors - VLA-4 Antagonists - Activated Protein C For more information visit http://www.researchandmarkets.com/research/sv...lomyelitis
CGEN: 8.12 (+0.21), ARRY: 3.84 (+0.27)
Stockboard Custom Reports on Resverlogix Corp. and Medicago Inc.
ACCESSWIRE - Tue Sep 03, 12:04PM CDT
Custom stock reports and email news alert service for Resverlogix Corp. (TSX:RVX) and Medicago Inc. (TSX: MDG) (OTCQX: MDCGF) are now available on Stockboard.com
RVX.TO: 0.64 (-0.03)
Resverlogix Announces a Corporate Update Conference Call & Webcast
PR Newswire - Thu Aug 29, 8:00AM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.64 (-0.03)
Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review - Latest Analysis
M2 - Wed Aug 21, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6pv5b7/prediabetesimpai) has announced the addition of the "Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2013" report to their offering. Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2013" provides data on the Pre-Diabetes/Impaired Glucose Tolerance clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pre-Diabetes/Impaired Glucose Tolerance. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pre-Diabetes/Impaired Glucose Tolerance. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles - Arete Therapeutics Inc. - Bayer AG - Bioneer Corporation - Cadila Pharmaceuticals Ltd. - Daiichi Sankyo Company, Limited - Forest Laboratories, Inc. - Generex Biotechnology Corporation - Genfit SA - KineMed, Inc. - Limerick BioPharma, Inc. - Marico Limited - Merck & Co., Inc. - New Chapter, Inc. - Novartis AG - Novo Nordisk A/S - NuMe Health LLC - Resverlogix Corp. - Sanofi - Takeda Pharmaceutical Company Limited - UnitedHealth Group Incorporated For more information visit http://www.researchandmarkets.com/research/6p...betesimpai
NVO: 43.50 (-2.30), UNH: 92.64 (+0.51), MRK: 55.85 (-0.60), FRX: 99.00 (-0.77), NVS: 92.35 (+2.14)
Resverlogix Corporation is Featured as the Daily Momentum Gainer to Watch on Smallcappower.com
Newsfile Corp - Fri Jul 05, 9:53AM CDT
full story)
IIROC Trade Resumption - Resverlogix Corp.
Newsfile Corp - Thu Jun 27, 1:10PM CDT
Trading resumes in:
Resverlogix Reports Top-Line Results from ASSURE Clinical Trial
PR Newswire - Thu Jun 27, 1:00PM CDT
Resverlogix Corp. (TSX:RVX) today announced that its Phase 2b ASSURE clinical trial evaluating RVX-208 in high-risk cardiovascular patients with low high-density lipoprotein (HDL) did not meet its primary endpoint of a -0.6% change in percent atheroma volume as determined by intravascular ultrasound (IVUS). The RVX-208 treated group had -0.4% plaque regression (p= 0.08). RVX-208 is Resverlogix's first-in-class orally active BET-protein inhibitor.
RVX.TO: 0.64 (-0.03)
IIROC Trade Halt - Resverlogix Corp.
Newsfile Corp - Thu Jun 27, 8:00AM CDT
The following issues have been halted by IIROC:
Zenith Epigenetics Corp. commences operations
PR Newswire - Mon Jun 03, 5:00PM CDT
Zenith Epigenetics Corp. ("Zenith"
commenced operations today as an early stage research company. Zenith was formed as a result of a plan of arrangement (the "Arrangement" involving Resverlogix Corp. ("Resverlogix" , RVX Therapeutics Inc. ("Therapeutics" and Zenith pursuant to which Resverlogix spun-out Therapeutics to Zenith. Shareholders of Resverlogix now own one new common share of Resverlogix and one common share of Zenith for each common share of Resverlogix held immediately prior to the Arrangement becoming effective.
RVX.TO: 0.64 (-0.03)
Resverlogix Corp. announces completion of spin-out transaction
PR Newswire - Mon Jun 03, 4:45PM CDT
Resverlogix Corp. ("Resverlogix" (TSX: RVX) today announced the successful completion of its previously announced Plan of Arrangement under the Business Corporations Act (Alberta) (the "Arrangement" pursuant to which Resverlogix spun-out RVX Therapeutics Inc. ("Therapeutics" to Zenith Epigenetics Corp. (formerly 1741273 Alberta Ltd.) ("Zenith" . Shareholders of Resverlogix now own one new common share of Resverlogix and one common share of Zenith for each common share of Resverlogix held immediately prior to the Arrangement becoming effective.
RVX.TO: 0.64 (-0.03)
RVXCF, TCEHY, WHX, TRMD, Removed From Naked Short Lists Today
M2 - Thu May 30, 9:02AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. RESVERLOGIX CORP (OTC:RVXCF), Tencent Holdings Ltd (OTC:TCEHY), Whiting USA Trust (NYSE:WHX), Torm A/S (NASDAQ:TRMD). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
WHX: 2.39 (-0.19)
Resverlogix Corp. shareholders approve plan of arrangement
PR Newswire - Tue May 28, 6:42PM CDT
Resverlogix Corp. ("Resverlogix" (TSX: RVX) announced today that holders ("Shareholders" of common shares of Resverlogix ("Resverlogix Shares" have approved the special resolution relating to the proposed spin-out of RVX Therapeutics Inc. ("Therapeutics" to Zenith Epigenetics Corp. (formerly 1741273 Alberta Ltd.), a newly-incorporated company ("Newco" , pursuant to a plan of arrangement under the Business Corporations Act (Alberta) (the "Arrangement" . Upon completion of the Arrangement, shareholders of Resverlogix will own one common share of Resverlogix and one common share of Newco for each common share of Resverlogix held immediately prior to the Arrangement becoming effective.
RVX.TO: 0.64 (-0.03)
Resverlogix Announces Details of Anticipated Distribution of Newco Shares
PR Newswire - Mon May 27, 4:45PM CDT
Resverlogix Corp. (TSX:RVX) ("Resverlogix" announced that further to its previously announced Plan of Arrangement (the "Arrangement" to spin-out its subsidiary RVX Therapeutics Inc. ("RVX Therapeutics" to Zenith Epigenetics Corp. (formerly 1741273 Alberta Ltd.), a newly-incorporated company ("Newco" , the record date for the distribution of common shares of Newco ("Newco Shares" is May 31, 2013. Upon completion of the Arrangement, shareholders of Resverlogix will own one common share of Resverlogix and one Newco Share for each common share of Resverlogix held immediately prior to the Arrangement becoming effective.
RVX.TO: 0.64 (-0.03)
RVXCF, Has Remained On Naked Short Lists 13 Consecutive Days
M2 - Mon May 27, 8:52AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Has Remained On the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. RESVERLOGIX CORP (OTC:RVXCF). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
NVGN, ABIO, RVXCF, QQEW, Added To Naked Short Lists Today
M2 - Thu May 09, 8:54AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), ARCA Biopharma Inc (NASDAQ:ABIO), RESVERLOGIX CORP (OTC:RVXCF), First Trust Portfolios LP (NASDAQ:QQEW). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
ABIO: 1.08 (-0.01), NVGN: 3.04 (-0.01), QQEW: 40.55 (+0.55)
Resverlogix Corporate Update Conference Call & Webcast Announcement
PR Newswire - Wed Oct 01, 1:00PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.64 (-0.03)
Resverlogix Corp. Closes Additional $30 million from Citibank Loan
PR Newswire - Fri Aug 15, 4:00PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.64 (-0.03)
Resverlogix Corp. Shareholders Approve Additional $30 million from Citibank Loan
PR Newswire - Wed Aug 13, 4:01PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.64 (-0.03)
Restenosis - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fzlqdr/restenosis) has announced the addition of the "Restenosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Restenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restenosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Restenosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Restenosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shire Plc - Resverlogix Corp. - CytoTools AG - Angelini Group - Viron Therapeutics, Inc. - AIM Therapeutics Inc. - CSPC NBP Pharmaceutical Co.,ltd - XBiotech USA, Inc. For more information visit http://www.researchandmarkets.com/research/fzlqdr/restenosis
SHPG: 197.80 (+1.93)
CounterPath to Present at Needham Growth Conference
Marketwire Canada - Thu Jan 09, 6:57PM CST
CounterPath Corporation (NASDAQ:CPAH)(TSX:CCV), an award-winning provider of desktop and mobile VoIP software products and solutions, announces that Donovan Jones, President and Chief Executive Officer, will present at the 16th Annual Needham Growth Conference. Mr. Jones will outline CounterPath's VoIP software and services, its customer relationships, its IP portfolio and the sector outlook.
CCV.TO: 1.15 (+0.20), CPAH: 1.04 (+0.15), ISIS: 46.43 (+0.57), MRK: 55.85 (-0.60), BMY: 54.20 (+0.67), MNTA: 11.08 (+0.11), NVS: 92.35 (+2.14)
Global Encephalomyelitis Pipeline Review Report - H2 2013
M2 - Fri Dec 20, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/svxp6q/encephalomyelitis) has announced the addition of the "Encephalomyelitis - Pipeline Review, H2 2013" report to their offering. 'Encephalomyelitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Encephalomyelitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Encephalomyelitis. Scope - A snapshot of the global therapeutic scenario for Encephalomyelitis. - A review of the Encephalomyelitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Encephalomyelitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Encephalomyelitis Therapeutics Development - Takeda Pharmaceutical Company Limited - Elan Corporation, plc - Hadasit Medical Research Services & Development Ltd - Compugen Ltd. - Array BioPharma Inc. - Resverlogix Corp. - KAHR medical Ltd. - Cognosci, Inc. - Encephalomyelitis - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Route of Administration - Assessment by Molecule Type Drug Profiles - IRX-5183 - KAHR-101 - KAHR-104 - COG-112 - Antiarrhythmic Drug - Phosphodiesterase Type 5 Inhibitors - Cholesterol Absorption Inhibitor - CGEN-15021 - CGEN-15091 - RVX-297 - AR-460770 - VCE-003 - VCE-004 - PP-090-45 - COG-133 - Thymulin - thymopentin - TAK-779 - Soluble Immune Response Suppressors - VLA-4 Antagonists - Activated Protein C For more information visit http://www.researchandmarkets.com/research/sv...lomyelitis
CGEN: 8.12 (+0.21), ARRY: 3.84 (+0.27)
Stockboard Custom Reports on Resverlogix Corp. and Medicago Inc.
ACCESSWIRE - Tue Sep 03, 12:04PM CDT
Custom stock reports and email news alert service for Resverlogix Corp. (TSX:RVX) and Medicago Inc. (TSX: MDG) (OTCQX: MDCGF) are now available on Stockboard.com
RVX.TO: 0.64 (-0.03)
Resverlogix Announces a Corporate Update Conference Call & Webcast
PR Newswire - Thu Aug 29, 8:00AM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.64 (-0.03)
Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review - Latest Analysis
M2 - Wed Aug 21, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6pv5b7/prediabetesimpai) has announced the addition of the "Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2013" report to their offering. Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2013" provides data on the Pre-Diabetes/Impaired Glucose Tolerance clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pre-Diabetes/Impaired Glucose Tolerance. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pre-Diabetes/Impaired Glucose Tolerance. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles - Arete Therapeutics Inc. - Bayer AG - Bioneer Corporation - Cadila Pharmaceuticals Ltd. - Daiichi Sankyo Company, Limited - Forest Laboratories, Inc. - Generex Biotechnology Corporation - Genfit SA - KineMed, Inc. - Limerick BioPharma, Inc. - Marico Limited - Merck & Co., Inc. - New Chapter, Inc. - Novartis AG - Novo Nordisk A/S - NuMe Health LLC - Resverlogix Corp. - Sanofi - Takeda Pharmaceutical Company Limited - UnitedHealth Group Incorporated For more information visit http://www.researchandmarkets.com/research/6p...betesimpai
NVO: 43.50 (-2.30), UNH: 92.64 (+0.51), MRK: 55.85 (-0.60), FRX: 99.00 (-0.77), NVS: 92.35 (+2.14)
Resverlogix Corporation is Featured as the Daily Momentum Gainer to Watch on Smallcappower.com
Newsfile Corp - Fri Jul 05, 9:53AM CDT
full story)
IIROC Trade Resumption - Resverlogix Corp.
Newsfile Corp - Thu Jun 27, 1:10PM CDT
Trading resumes in:
Resverlogix Reports Top-Line Results from ASSURE Clinical Trial
PR Newswire - Thu Jun 27, 1:00PM CDT
Resverlogix Corp. (TSX:RVX) today announced that its Phase 2b ASSURE clinical trial evaluating RVX-208 in high-risk cardiovascular patients with low high-density lipoprotein (HDL) did not meet its primary endpoint of a -0.6% change in percent atheroma volume as determined by intravascular ultrasound (IVUS). The RVX-208 treated group had -0.4% plaque regression (p= 0.08). RVX-208 is Resverlogix's first-in-class orally active BET-protein inhibitor.
RVX.TO: 0.64 (-0.03)
IIROC Trade Halt - Resverlogix Corp.
Newsfile Corp - Thu Jun 27, 8:00AM CDT
The following issues have been halted by IIROC:
Zenith Epigenetics Corp. commences operations
PR Newswire - Mon Jun 03, 5:00PM CDT
Zenith Epigenetics Corp. ("Zenith"
commenced operations today as an early stage research company. Zenith was formed as a result of a plan of arrangement (the "Arrangement" involving Resverlogix Corp. ("Resverlogix" , RVX Therapeutics Inc. ("Therapeutics" and Zenith pursuant to which Resverlogix spun-out Therapeutics to Zenith. Shareholders of Resverlogix now own one new common share of Resverlogix and one common share of Zenith for each common share of Resverlogix held immediately prior to the Arrangement becoming effective. RVX.TO: 0.64 (-0.03)
Resverlogix Corp. announces completion of spin-out transaction
PR Newswire - Mon Jun 03, 4:45PM CDT
Resverlogix Corp. ("Resverlogix"
(TSX: RVX) today announced the successful completion of its previously announced Plan of Arrangement under the Business Corporations Act (Alberta) (the "Arrangement" pursuant to which Resverlogix spun-out RVX Therapeutics Inc. ("Therapeutics" to Zenith Epigenetics Corp. (formerly 1741273 Alberta Ltd.) ("Zenith" . Shareholders of Resverlogix now own one new common share of Resverlogix and one common share of Zenith for each common share of Resverlogix held immediately prior to the Arrangement becoming effective. RVX.TO: 0.64 (-0.03)
RVXCF, TCEHY, WHX, TRMD, Removed From Naked Short Lists Today
M2 - Thu May 30, 9:02AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. RESVERLOGIX CORP (OTC:RVXCF), Tencent Holdings Ltd (OTC:TCEHY), Whiting USA Trust (NYSE:WHX), Torm A/S (NASDAQ:TRMD). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
WHX: 2.39 (-0.19)
Resverlogix Corp. shareholders approve plan of arrangement
PR Newswire - Tue May 28, 6:42PM CDT
Resverlogix Corp. ("Resverlogix"
(TSX: RVX) announced today that holders ("Shareholders" of common shares of Resverlogix ("Resverlogix Shares" have approved the special resolution relating to the proposed spin-out of RVX Therapeutics Inc. ("Therapeutics" to Zenith Epigenetics Corp. (formerly 1741273 Alberta Ltd.), a newly-incorporated company ("Newco" , pursuant to a plan of arrangement under the Business Corporations Act (Alberta) (the "Arrangement" . Upon completion of the Arrangement, shareholders of Resverlogix will own one common share of Resverlogix and one common share of Newco for each common share of Resverlogix held immediately prior to the Arrangement becoming effective. RVX.TO: 0.64 (-0.03)
Resverlogix Announces Details of Anticipated Distribution of Newco Shares
PR Newswire - Mon May 27, 4:45PM CDT
Resverlogix Corp. (TSX:RVX) ("Resverlogix"
announced that further to its previously announced Plan of Arrangement (the "Arrangement" to spin-out its subsidiary RVX Therapeutics Inc. ("RVX Therapeutics" to Zenith Epigenetics Corp. (formerly 1741273 Alberta Ltd.), a newly-incorporated company ("Newco" , the record date for the distribution of common shares of Newco ("Newco Shares" is May 31, 2013. Upon completion of the Arrangement, shareholders of Resverlogix will own one common share of Resverlogix and one Newco Share for each common share of Resverlogix held immediately prior to the Arrangement becoming effective. RVX.TO: 0.64 (-0.03)
RVXCF, Has Remained On Naked Short Lists 13 Consecutive Days
M2 - Mon May 27, 8:52AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Has Remained On the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. RESVERLOGIX CORP (OTC:RVXCF). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
NVGN, ABIO, RVXCF, QQEW, Added To Naked Short Lists Today
M2 - Thu May 09, 8:54AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), ARCA Biopharma Inc (NASDAQ:ABIO), RESVERLOGIX CORP (OTC:RVXCF), First Trust Portfolios LP (NASDAQ:QQEW). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
ABIO: 1.08 (-0.01), NVGN: 3.04 (-0.01), QQEW: 40.55 (+0.55)
